Therapeutic effect of brain protein hydrolysate and simvastatin on carotid atherosclerotic plaques in CI patients and its influence on LVEF and CRP level / 心血管康复医学杂志

ABSTRACT

Objective: To explore clinical value of brain protein hydrolysate (BPH ) and simvastatin in treatment of patients with cerebral infarction (CI) complicated carotid atherosclerotic plaques (CAP).Methods: A total of 90 CI + CAP patients treated in our hospital from Mar 2016 to May 2017 were selected ,randomly and equally divided into routine treatment group and combined treatment group (received simvastatin + BPH based on routine treat-ment) ,both groups were treated for four weeks- Therapeutic effect ,United States National Institutes of Health Stroke Score (NIHSS) ,CAP-related indexes ,hemorheology indexes ,LVEF and CRP before and after treatment and incidence of adverse events were compared between two groups .Results: Compared with routine treatment group after treatment ,there were significant reductions in NIHSS score [ (15-56 ± 6-33) scores vs.(12-14 ± 3-18) scores] ,CAP size [ (1-54 ± 0-32) cm2 vs.(1-34 ± 0-30) cm2 ] ,intima-media thickness [ (1-37 ± 0-08) mm vs. (1-15 ± 0-04) mm] ( P＜0-01 all) ,and significant rise in total effective rate (80-00% vs.95-56%, P＝0-024) in combined treatment group ; there were significant reductions in hematocrit [ (44-24 ± 3-24 )% vs.(37-72 ± 2-41)%] ,platelet aggregation rate [ (45-62 ± 15-95)% vs.(38-10 ± 2-52)%] ,fibrinogen [ (4-06 ± 1-43) g／L vs. (3-18 ± 1-15) g／L] ,whole blood viscosity [ (2-66 ± 0-77) mPa·s vs.(1-55 ± 0-25) mPa·s] ,plasma viscosity [ (1-45 ± 0-11) mPa·s vs.(1-21 ± 0-16) mPa·s] and serum CRP level [ (4-36 ± 1-03) mg／L vs.(1-70 ± 0-20) mg／L] ,and significant rise in LVEF [ (49-30 ± 3-74)% vs.(56-67 ± 4-37)%] in combined treatment group , P＜0-01 all- Incidence rate of cardio-and cerebrovascular events in combined treatment group was significantly lower than that of routine treatment group (4-44% vs.17-18%, P＝ 0-004 ).Conclusion: Simvastatin combined BPH based on routine treatment can achieve better total therapeutic effect and reduce incidence rate of complications in CI + CAP patients .